Skip to main content
Clinical Trials/NCT04820959
NCT04820959
Completed
Not Applicable

Validation of New Therapeutic Targets to Prevent Collagen Accumulation During Cardiac Fibrosis: Procollagen C-proteinase Enhancers

Centre Hospitalier Universitaire Dijon1 site in 1 country66 target enrollmentOctober 4, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Valvulopathy
Sponsor
Centre Hospitalier Universitaire Dijon
Enrollment
66
Locations
1
Primary Endpoint
Myocardial fibrosis rate
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Heart failure is characterized by cardiac fibrosis linked to extracellular collagen deposits. Collagens are synthesized as soluble precursors, procollagens, which must undergo proteolytic maturation to assemble into fibres. This step is under the control of two extracellular proteins, procollagen C-proteinase enhancer 1 and 2 (PCPE-1 and -2). The mechanism of action of these highly effective and specific activators was recently elucidated by one of our partners. Preliminary results, as well as data from the literature, indicate a strong correlation between the expression rates of PCPEs and cardiac fibrosis. The aim of this study is to validate in humans, by analysis of endomyocardial tissue biopsies, the hypothesis that PCPEs contribute to the anarchic accumulation of collagen during cardiac fibrosis and to evaluate the interest of developing new diagnostic and therapeutic strategies for cardiac fibrosis using PCPE agonists.

Registry
clinicaltrials.gov
Start Date
October 4, 2020
End Date
July 7, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Person who has given written consent
  • Patient aged 18 to 85 for men and 60 to 85 for women
  • Patient requiring cardiac surgery for aortic valve replacement or aortic plastic surgery or aortic plasty or ascending aorta replacement more or less associated with aortic valve surgery

Exclusion Criteria

  • Person not affiliated or not benefiting from national health insurance
  • Person subject to a measure of legal protection (curatorship, guardianship)
  • Person deprived of liberty, by judicial or administrative decision
  • Major incapable or incapable of giving consent
  • Pregnant or breastfeeding woman
  • Emergency Surgery
  • Acute Infectious Endocarditis

Outcomes

Primary Outcomes

Myocardial fibrosis rate

Time Frame: Through study completion, an average of 1 year

Measurement of the level of myocardial fibrosis in myocardial tissue.

Rate of PCPE-1/2

Time Frame: Through study completion, an average of 1 year

Measurement of PCPE-1/2 rate in myocardial tissue.

Study Sites (1)

Loading locations...

Similar Trials